CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 7 enrolled
Drug / intervention
ertapenemdrug
Likely dose
ertapenem 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00939952
NCT00939952Phase 4Completed
CompareCT.gov

Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis

Albany College of Pharmacy and Health Sciences·interventional·Posted Jul 15, 2009·Updated Feb 26, 2013

In Brief

A Phase 4 clinical trial evaluating ertapenem for Continuous Ambulatory Peritoneal Dialysis and End Stage Renal Disease. Completed, enrolled 7 participants across 1 site.

Detailed Summary

The objective of this study is to characterize the pharmacokinetic profile of ertapenem during continuous ambulatory peritoneal dialysis (CAPD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContinuous Ambulatory Peritoneal Dialysis, End Stage Renal Disease
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 15, 2009
Enrollment StartJun 1, 2009
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.0 years ago

Interventions

ertapenemdrug

500 mg IV once